Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAF1 | P04049 | 5/20 | 0.38 |
| ▸ | BRAF | P15056 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163340 | 0.93 | SCN10A (0.37) | THRBSMN1; SMN2JAK3MAPTNPSR1 | |
| SCHEMBL6165622 | 0.93 | SCN10A (0.39) | SMN1; SMN2JAK3MAPTNPSR1 | |
| SCHEMBL6435938 | 0.91 | KDR (0.34) | THRBLMNAJAK2JAK3 | |
| SCHEMBL7046359 | 0.90 | KDM4E (0.44) | THRBSMN1; SMN2KDM4ELMNAJAK2 | |
| SCHEMBL6435476 | 0.84 | KDR (0.36) | — | |
| SCHEMBL5562672 | 0.83 | SCN9A (0.43) | KDM4ERAF1BRAFTSHRHPGD | |
| SCHEMBL6165337 | 0.83 | MAPT (0.37) | JAK3KMT2AALDH1A1MAPTTSHR | |
| SCHEMBL6434527 | 0.83 | AAK1 (0.38) | KMT2A | |
| SCHEMBL6163566 | 0.82 | KDR (0.35) | LMNA | |
| SCHEMBL6163857 | 0.82 | AAK1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379522-B1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | BDKRB1, BDKRB2, GRIN1 | THRB 2773/4885SMN1; SMN2 306/4885KDM4E 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.